NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date and time:** Tuesday 4 October 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Dr Alex Cale Present for all items
5. Michael Chambers Present for all items
6. Dr Prithwiraj Das Present for all items
7. Chamkhor Dhillon Present for all items
8. Dr David Foreman Present for all items
9. Dr Rob Forsyth Present for all items
10. Dr Pedro Saramago Goncalves Present for all items
11. Dr Natalie Hallas Present for all items
12. John Hampson Present for all items
13. Dr Nigel Langford Present for all items
14. Dr Andrea Manca Present for all items
15. Iain McGowan Present for all items
16. Ugochi Nwulu Items 6 to 6.2.2
17. Stella O’Brien Present for all items
18. Professor Subhash Pokhrel Items 1 to 4.3.2
19. Professor Matthew Stevenson Items 6 to 6.2.2
20. Professor Paul Tappenden Items 1 to 5.2.2

NICE staff present

Jasdeep Hayre, Associate Director Items 1 to 4.3.2

Ross Dent, Associate Director Items 5 to 6.2.2

Louise Jafferally, Project Manager Present for all items

Celia Mayers, Project Manager Items 1 to 4.3.2

Sally Doss, Heath Technology Assessment Adviser Items 1 to 4.3.2

Alex Filby, Heath Technology Assessment Adviser Items 6 to 6.2.2

Anne Murray-Cota, Heath Technology Assessment Analyst Items 1 to 4.3.2

Catie Parker, Heath Technology Assessment Analyst Items 5 to 5.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 6 to 6.2.2

Benjamin Gregory, Business Analyst, RIA Items 5 to 6.2.2

Catrin Austin, Technical Analyst, Commercial Risk Assessment Items 1 to 4.3.2

Korin Knight, Senior Medical Editor Items 1 to 4.3.2

Anna Sparshatt, Senior Medical Editor Items 5 to 5.2.2

Emilene Coventry, Senior Medical Editor Items 6 to 6.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.3.2

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Leah Kelly, Administrator, TA Items 1 to 4.3.2

Iain Cannell, Administrator, TA Items 5 to 6.2.2

NICE staff observers present

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment, Items 1 to 4.3.2 & 6 to 6.2.2

Catrin Austin, Technical Analyst, Methods, and economics Items 1 to 4.3.2

Summaya Mohammed, Heath Technology Assessment Analyst Items 1 to 4.3.2

Lewis Ralph, Heath Technology Assessment Analyst Items 6 to 6.2.2

Stephen Duffield, Senior Adviser in Data and Analytics Items 1 to 4.3.2

Jen Hacking, Medical Editor Items 1 to 4.3.2

Ian Watson, Heath Technology Assessment Adviser Items 5 to 5.2.2

Oyewumi Afolabi, Technical Analyst, PASLU Items 6 to 6.2.2

External assessment group representatives present,

Matt Stevenson, School of Health and Related Research (ScHARR), Items 1 to 4.2.1 & 5 to 5.1.3

Andrew Metry, School of Health and Related Research (ScHARR), Items 1 to 4.2.1 & 5 to 5.1.3

Paul Tappenden, School of Health and Related Research (ScHARR), Items 6 to 6.1.3

Katy Cooper, School of Health and Related Research (ScHARR), Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 4.3.2 & 6 to 6.2.2

Professor David Marks, Clinical expert, nominated by Kite, a Gilead company, Items 1 to 4.1.3

Sophie Wheldon, Patient expert, nominated by Leukaemia Care, Items 1 to 4.1.3

Dr Deborah Yallop, Clinical expert, nominated by Royal College of Physicians, Items 1 to 4.1.3

Vanessa Hebditch, Patient expert, nominated by the British Liver Trust, Items 6 to 6.1.3

Dr Richard Hubner, Clinical expert, nominated by BASL, Items 6 to 6.1.3

Professor Tim Meyer, Clinical expert, nominated by Ipsen, Items 6 to the start of 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 6 September 2022.

### Appraisal of autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults [ID1494]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Kite, a Gilead company.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has participated in an advisory panel for Pfizer (possible comparator), in an unrelated disease area (prostate cancer). It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Novartis in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
* Committee member Stella O’Brien declared personal interests as she is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK’s research and academic communities. Although CAR-T therapies are an example of ATMPs, I have not contributed to work on CAR-T therapies with this group. It was agreed her declaration would not prevent Stella from participating in discussions on this appraisal.
* Committee member Professor Paul Tappenden declared non-financial professional interests as he works for ScHARR (EAG for this topic), and he provided a peer review of the draft ERG report. It was agreed that his declaration means he can contribute to the discussion but not take part in any vote.
* Nominated clinical expert Dr Deborah Yallop declared the following interests:
* She has received honoraria for advisory board for Kite Gilead and Pfizer
* She has received financial support to attend meetings from Amgen, Servier, Jazz
* She provides Project support to Servier
* She is a principal investigator KCH AUTO-1 trial (Autolus)
* She has been co-investigator on the CALM trial (Servier)).

It was agreed her declarations would not prevent Dr Yallop from providing expert advice to the committee.

* Nominated patient expert Sophie Wheldon declared the following interests:
* She took part in a patient and carer insights workshop on CAR T with Janssen in mid-2021 and received £240
* She has been diagnosed with ALL and received CAR-T therapy.
* She is employed by the nominating organisation Leukaemia Care who in the last 12 months received funding from Amgen, Incyte, Novartis, and Pfizer.

It was agreed her declarations would not prevent Sophie from providing expert advice to the committee

* Nominated clinical expert Professor David Marks declared financial interests as he has been remunerated for work for Pfizer, Amgen, Novartis, and Kite in the area of ALL It was agreed his declarations would not prevent Professor Marks from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Rob Forsyth, Dr Nigel Langford, and Stella O’Brien
  1. Part 2a – Closed session (members of the public, company representatives, clinical and patient experts were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10424>

### Appraisal of trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (Rapid Review of TA669) [ID6167]

* 1. Part 1 – Closed session
     1. The chair Professor Stephen O’Brien welcomed the external assessment group representatives and company representatives from Servier.
     2. The chair asked all committee members, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Paul Tappenden declared non-financial professional interests as he works for ScHARR (EAG for this topic). He had no involvement in the topic. It was agreed his declaration would not prevent Professor Tappenden from participating in discussions on this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee.
  1. Part 2 – Closed session (company representatives and external assessment group representatives were asked to leave the meeting).
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11159>

### Appraisal of cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Ipsen.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Matt Stevenson declared non-financial professional interests as he works for ScHARR (ERG for this topic). He had no involvement in the topic. It was agreed his declaration would not prevent Professor Stevenson from participating in discussions on this appraisal.
* Nominated clinical expert Professor Tim Meyer declared financial interests as he has been paid as a consultant on occasional advisory boards by Adaptimmune, AstraZeneca, BMS, Boston Scientific, Eisai, Ipsen, and Roche and received consultancy for Geneos. It was agreed his declarations would not prevent Professor Meyer from providing expert advice to the committee.
* Nominated patient expert Vanessa Hebditch indirect financial interests as her employer the British Liver Trust, received an educational grant of £10,600 from Ipsen for the production of patient materials for liver cancer patients and in support of raising awareness and launching these materials during Liver Cancer Awareness Month in October 2021. Ipsen had no control or influence over the content or promotion of these materials which were co-produced by patients, carers, and clinical experts. It was agreed her declarations would not prevent Vanessa from providing expert advice to the committee.
* Nominated clinical expert Dr Richard Hubner declared direct financial interests as he has :
* Attended advisory boards for Roche, BMS, Eisai, Celgene, Beigene, Ipsen and BTG.
* Received speaker fees from Eisai, Ipsen, Mylan and PrimeOncology.
* Trial steering committee membership for Beigene and Ipsen.
* Received conference attendance support from Bayer, BMS and Roche.

It was agreed his declarations would not prevent Dr Hubner from providing expert advice to the committee.

* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Natalie Hallas, Dr Alex Cale, and Stella O’Brien
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10805>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 1 November 2022 and will start promptly at 09.30.